Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Chronic lymphocytic leukemia (CLL) patients refractory to covalent Bruton's tyrosine kinase (BTK) and BCL2 inhibitors face limited treatment options and poor outcomes.
• Standard therapies provide short-lived disease control and reduced overall survival, highlighting an unmet clinical need for effective salvage treatments.

Purpose of the Study:

• To review emerging treatment strategies for CLL patients who are refractory to existing targeted therapies.
• To evaluate the efficacy of noncovalent BTK inhibitors and anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in this patient population.
• To discuss the role of allogeneic stem cell transplantation and novel therapeutic approaches.

Main Methods:

• Review of current literature and clinical trial data on novel therapies for refractory CLL.
• Analysis of response rates and outcomes for noncovalent BTK inhibitors and CAR T-cell therapy.
• Consideration of allogeneic stem cell transplantation and future therapeutic strategies.

Main Results:

• Noncovalent BTK inhibitors demonstrate approximately 70% overall response rates in patients resistant or intolerant to covalent BTK inhibitors.
• Anti-CD19 CAR T-cell therapy achieves complete responses in up to 45% of cases, with a 65% undetectable measurable residual disease rate in bone marrow.
• Allogeneic stem cell transplantation outcomes appear unaffected by prior targeted agent exposure in young, fit patients.

Conclusions:

• Noncovalent BTK inhibitors and anti-CD19 CAR T-cell therapy represent promising, albeit unapproved, options for refractory CLL.
• Allogeneic stem cell transplantation should be considered for eligible patients.
• Further research into novel agents targeting different CLL survival pathways is essential.